New CSX_BLUE_RGB_JPG.jpg
CSX Corporation Announces Date for Third Quarter Earnings Release and Earnings Call
September 24, 2024 12:00 ET | CSX Corporation
JACKSONVILLE, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- CSX Corp. (NASDAQ: CSX) will release third quarter financial and operating results after the market close on Wednesday, October 16, 2024. This...
Molecure_logo-removebg-preview.png
Molecure has published its financial report for 2023 - the company has significantly accelerated the development of its clinical and pre-clinical programmes and plans to make strong progress in research in 2024 and 2025
April 03, 2024 04:00 ET | Molecure
Initiation of Phase II clinical trial of OATD-01 (KITE) for the treatment of pulmonary sarcoidosis following approval from the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare...
Sol Gel - New Logo - light.jpg
Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments
March 13, 2024 07:00 ET | Sol-Gel Technologies Ltd.
Sol-Gel Reports Full Year 2023 Financial Results and Corporate Developments
dfds-logo-2021-group-blue-rgb.png
DELÅRSRAPPORT 3. KVT. 2023: FORVENTNING FORBEDRET AF SOLIDT KVARTAL
November 15, 2023 01:30 ET | DFDS A/S
SELSKABSMEDDELELSE NR. 37/2023 Bedre end forventet EBITDA for 3. kvartal på DKK 1,6 mia.Stærk højsæson for passagererFragtresultat som forventet lavere end sidste årCash flow yderligere...
dfds-logo-2021-group-blue-rgb.png
Q3 2023 INTERIM REPORT: OUTLOOK FIRMED UP BY SOLID QUARTER
November 15, 2023 01:30 ET | DFDS A/S
ANNOUNCEMENT NO. 37/2023 Q3 EBITDA of DKK 1.6bn was ahead of expectationsStrong passenger high seasonFreight performance as expected below last yearCash flow further improvedEBITDA...
Infant Bacterial The
Infant Bacterial Therapeutics AB (publ), Delårsrapport 1 januari – 30 juni 2023
August 25, 2023 02:30 ET | Infant Bacterial Therapeutics AB
VD Kommentarer Vår Fas III-studie, den största studien av sitt slag som någonsin genomförts, fortskrider på 88 sjukhus och i tio länder. Vi har nu rekryterat 85% av patienterna (1824 av de...
Infant Bacterial The
Infant Bacterial Therapeutics AB (publ) Interim report January 1 - June 30, 2023
August 25, 2023 02:30 ET | Infant Bacterial Therapeutics AB
Message from the CEO Our Phase-III study, the largest of its kind ever conducted, is progressing across 88 hospitals in ten countries. We have now recruited 85% of the patients (1824 out of the...
Pieridae logo_Hunter.jpg
Pieridae Releases Q2 2023 Results
August 09, 2023 18:23 ET | Pieridae Alberta Production Ltd.
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR DISSEMINATION IN UNITED STATES CALGARY, Alberta, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Pieridae Energy Limited (“Pieridae” or the...
Kaplan Fox Tagline Logo Color.jpg
SEA LIMITED INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies Sea Limited Investors of a Class Action Lawsuit and Upcoming Deadline
August 03, 2023 09:00 ET | Kaplan Fox & Kilsheimer LLP
NEW YORK, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed on behalf of purchasers or acquirers of Sea Limited (“Sea” or the...
jotul.png
INTERIM FINANCIAL REPORT Q1 2023 - Jøtul AS
May 31, 2023 02:15 ET | Jøtul AS
The Jøtul Group (representing Jøtul AS together with its subsidiaries) is one of the three largest suppliers of fireplaces in Europe and a significant player in North America. The company, with a...